Form 4: Neuraxis Officer Granted 47,569 RSUs

Neuraxis, Inc. officer Thomas Carrico received a grant of 47,569 restricted stock units vesting over three years.

Summary

• Thomas Joeseph Carrico, CRO, CCO, and CPO of Neuraxis, INC (NRXS), was granted 47,569 Restricted Stock Units (RSUs).
• The grant date for these RSUs was January 22, 2026.
• The RSUs were granted as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended.
• These RSUs will vest in three equal annual installments over a three-year period.
• The implied price of the derivative security (RSU) was $4.63.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine event. It signifies continued executive incentive and alignment with shareholder interests, which is generally favorable, but does not represent a new strategic development.

Positives

• The grant of RSUs aligns management's interests with shareholders through equity compensation.
• The vesting schedule encourages long-term commitment from a key officer.

Negatives

• No immediate cash benefit for the officer until vesting occurs.
• Potential for minor dilution for existing shareholders upon vesting and conversion to common stock.

Risks

• Future stock price volatility could impact the value of the RSUs upon vesting.
• The officer's continued employment is required for the RSUs to vest.

Future Outlook

The grant of restricted stock units with a three-year vesting schedule indicates a long-term incentive for the officer, aligning future performance with equity value.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units, is a standard practice across various industries, especially in biotechnology and healthcare, to attract, retain, and incentivize key executives. This aligns the interests of management with long-term shareholder value creation, a common strategy seen in companies like Moderna or Regeneron Pharmaceuticals.

Comparison to Industry Standards

• The grant of RSUs as a form of executive compensation is a common practice, comparable to compensation structures at biotech peers such as BioNTech or Vertex Pharmaceuticals, which frequently use equity to incentivize leadership.
• The three-year vesting schedule is standard for such grants, promoting long-term commitment, similar to what is observed in compensation plans at companies like Gilead Sciences or Amgen.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned management incentives, but also potential for minor dilution upon vesting.
• Employees (specifically Thomas Carrico): Increased personal stake in the company's performance and long-term compensation.

Next Steps

• The RSUs will vest in three equal annual installments over a three-year period, starting from the grant date of January 22, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key officer. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the company's valuation or strategic outlook to warrant a change in investment recommendation. It's an expected part of executive compensation.

Keywords

Neuraxis, NRXS, Form 4, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Officer Grant, Thomas Carrico